Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The head space of 2C-T-7 is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
The visual geometry of 2C-T-7 can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, sharp in their edges and equally rounded and angular in their corners. They give off a contradictory natural and synthetic feel with slightly more mystical and shamanic undertones to them in comparison to other phenethylamines. At higher dosages they are equally likely to result in states of Level 7A visual geometry and Level 7B. The visual geometry is extremely similar to 2C-E and 2C-P and can be described as equal in intensity or complexity.
2C-T-7 produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.
The auditory effects of 2C-T-7 are more common in their occurrence than many more commonly used psychedelics.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-7 is not habit-forming and is unlikely to cause psychological dependence. The desire to use it often decreases with repeated use, and it is described as self-regulating by most users.
2C-T-7 is not physically addicting. Withdrawal effects following discontinuation have not been reported.
At least three deaths have been associated with 2C-T-7 use as of August 2007. These occurred primarily with insufflated doses of 30-35 mg, characterized by the DEA as excessive. All reported fatalities involved either uncommonly large insufflated doses or co-ingestion of other stimulants such as MDMA or ephedrine. No formal toxicological evaluation of 2C-T-7 has been conducted. The oral route appears to have a wider safety margin than insufflation, though exact lethal thresholds remain undetermined.
Insufflation of 2C-T-7 causes intense burning pain lasting 5-15 minutes, leaves an unpleasant drip, and can lead to sinus and throat infections with repeated use; oral administration does not carry this risk.
At high doses, 2C-T-7 can produce severe dissociation and delirium characterized by complete disorientation, memory loss, confusion about having ingested a substance, and in some cases belligerent or violent behavior. These effects are dose-dependent and primarily associated with doses exceeding typical recreational ranges, particularly via insufflation. At typical oral doses, the headspace is described as relatively clear and insightful. Individuals with a family history of schizophrenia or early onset mental illness are advised to exercise extreme caution as psychedelics may trigger latent psychological conditions.
Muscle tremors and convulsions are listed among possible negative effects. Individuals with pre-existing seizure or convulsive disorders are warned they may be at elevated risk when using this substance.
2C-T-7 was developed around 1980 by Alexander Shulgin and Peyton Jacob III as part of Shulgin's extensive research program into substituted phenethylamines. The compound was first described in scientific literature by Myron Stolaroff by 1990, with more detailed characterization published by Shulgin…
European Council Decision (November 2003) - Member states required to implement control measures and criminal penalties within three months
Covered by analogue drug laws and formally added to Schedule 9 (the most restrictive category) by the National Drugs and Poisons Schedule Committee in 2005.
Added to the list of illegal psychotropic substances on November 8, 2004.
Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the 2C-phenethylamine catch-all provision.
Added to category B of the controlled substances list on August 23, 2003.
Scheduled under the government decree on substances, preparations, and plants considered to be narcotic drugs.
Became a controlled substance on February 18, 2003.
Classified as a Schedule I controlled substance. Possession, production, and distribution are prohibited.
Reported as a Schedule I controlled substance. Possession, production, and distribution are prohibited.
Added to Grade 2 (equivalent to Schedule II under the 1971 UN Convention on Psychotropic Substances) in October 2009.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Classified as Schedule I by emergency DEA ruling on September 20, 2002. Permanently placed in Schedule I on March 18, 2004 when the DEA published a Final Rule in the Federal Register (69 FR 12794). Manufacturing, buying, possessing, or distributing without a DEA license is illegal.
Prohibited under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal.
Possession, production, and sale are illegal. Listed on Portaria SVS/MS nº 344 as of February 18, 2014.
Controlled substance as of October 2015. Illegal to sell, buy, import, export, and manufacture.
Added to Schedule I in February 2011 alongside several other novel psychoactive substances.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) as of July 1, 2001. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing are illegal without a license.
Added to Tabella I (list of prohibited plants and substances) by Ministry of Health statement on January 11, 2005.
The first country to ban 2C-T-7 after brief availability in smartshops. Following the ban on 2C-T-2, 2C-T-7 appeared on the market but was quickly prohibited under List I of the Opium Law.
Legislation enacted in January 2005 to control 2C-T-7 alongside 2C-I, 2C-T-2, and TMA-2.
First classified as a health hazard under the Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:58) as of April 1, 1999, making it illegal to sell or possess. Subsequently added to Schedule I as of March 16, 2004.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 as a result of the phenethylamine catch-all clause. In 1999, the Home Office effectively placed all compounds listed in PiHKAL into Class A.
16 sources cited
